TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I-II Randomized Autologous Bone Marrow Derived Aldehyde Dehydrogenase-Bright (ALDHbr) Cells Against Unfractionated Autologous Mononuclear Bone Marrow in Patients With Rutherford 4 or 5 Peripheral Arterial Occlusive Disease
Brief Summary: This study will treat patients with such severe lower leg ischemia or vascular compromise that they have pain at rest. The goal is to compare treatment of the patient's painful disorder by injecting cells into the calf of the leg and testing for circulatory improvement. A treatment will given at random to two groups and will be injection into the calf muscle with ALD-301 (specially processed stem and progenitor cells) from the patient's own bone marrow, or with cells processed by more routine that minimally purifies the cells. The study goal is to see if the ALD-301 cells are more effective in generating new small blood vessels to improve the circulation to the affected leg.


Options:
A: Arm Label: becaplermin gel; Type: EXPERIMENTAL; Interventions: Drug: becaplermin gel | Arm Label: Duoderm Hydrogel™; Type: ACTIVE_COMPARATOR; Interventions: Drug: Duoderm Hydrogel™ | Intervention Type: DRUG; Name: becaplermin gel; Assigned to Arm(s): becaplermin gel | Intervention Type: DRUG; Name: Duoderm Hydrogel™; Assigned to Arm(s): Duoderm Hydrogel™
B: Arm Label: NV1FGF 500 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Arm Label: NV1FGF 2000 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Arm Label: NV1FGF 4000 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): NV1FGF 2000 μg, NV1FGF 4000 μg, NV1FGF 500 μg
C: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: ALDH-br bone marrow cells vs. mononuclear bone marrow cells | Intervention Type: PROCEDURE; Name: ALDH-br bone marrow cells vs. mononuclear bone marrow cells; Assigned to Arm(s): 2
D: Arm Label: GSK1278863 5mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 100mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GSK1278863; Assigned to Arm(s): GSK1278863 100mg, GSK1278863 5mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I-II Randomized Autologous Bone Marrow Derived Aldehyde Dehydrogenase-Bright (ALDHbr) Cells Against Unfractionated Autologous Mononuclear Bone Marrow in Patients With Rutherford 4 or 5 Peripheral Arterial Occlusive Disease
Brief Summary: This study will treat patients with such severe lower leg ischemia or vascular compromise that they have pain at rest. The goal is to compare treatment of the patient's painful disorder by injecting cells into the calf of the leg and testing for circulatory improvement. A treatment will given at random to two groups and will be injection into the calf muscle with ALD-301 (specially processed stem and progenitor cells) from the patient's own bone marrow, or with cells processed by more routine that minimally purifies the cells. The study goal is to see if the ALD-301 cells are more effective in generating new small blood vessels to improve the circulation to the affected leg.


Options:
A: Arm Label: Allogeneic Mesenchymal Stromal Cell; Type: EXPERIMENTAL; Interventions: Drug: Allogeneic Mesenchymal Stromal Cell | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Allogeneic Mesenchymal Stromal Cell; Assigned to Arm(s): Allogeneic Mesenchymal Stromal Cell | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: ALDH-br bone marrow cells vs. mononuclear bone marrow cells | Intervention Type: PROCEDURE; Name: ALDH-br bone marrow cells vs. mononuclear bone marrow cells; Assigned to Arm(s): 2
C: Arm Label: 4times injection; Type: EXPERIMENTAL; Interventions: Biological: 4times injection | Arm Label: one injection; Type: EXPERIMENTAL; Interventions: Biological: stem cell transplantation | Intervention Type: BIOLOGICAL; Name: 4times injection; Assigned to Arm(s): 4times injection | Intervention Type: BIOLOGICAL; Name: stem cell transplantation; Assigned to Arm(s): one injection
D: Arm Label: MultiGeneAngio; Type: EXPERIMENTAL; Interventions: Biological: MultiGeneAngio | Intervention Type: BIOLOGICAL; Name: MultiGeneAngio; Assigned to Arm(s): MultiGeneAngio

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I-II Randomized Autologous Bone Marrow Derived Aldehyde Dehydrogenase-Bright (ALDHbr) Cells Against Unfractionated Autologous Mononuclear Bone Marrow in Patients With Rutherford 4 or 5 Peripheral Arterial Occlusive Disease
Brief Summary: This study will treat patients with such severe lower leg ischemia or vascular compromise that they have pain at rest. The goal is to compare treatment of the patient's painful disorder by injecting cells into the calf of the leg and testing for circulatory improvement. A treatment will given at random to two groups and will be injection into the calf muscle with ALD-301 (specially processed stem and progenitor cells) from the patient's own bone marrow, or with cells processed by more routine that minimally purifies the cells. The study goal is to see if the ALD-301 cells are more effective in generating new small blood vessels to improve the circulation to the affected leg.


Options:
A: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: ALDH-br bone marrow cells vs. mononuclear bone marrow cells | Intervention Type: PROCEDURE; Name: ALDH-br bone marrow cells vs. mononuclear bone marrow cells; Assigned to Arm(s): 2
B: Intervention Type: DEVICE; Name: Bone marrow concentration device; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intraarterial stem cell therapy, Other: Stem cells | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Procedure: intraarterial stem cell therapy, Other: Stem cells | Intervention Type: PROCEDURE; Name: intraarterial stem cell therapy; Assigned to Arm(s): 1, 2 | Intervention Type: OTHER; Name: Stem cells; Assigned to Arm(s): 1, 2
D: Arm Label: Active/Treatment Group; Type: EXPERIMENTAL; Interventions: Biological: Allogeneic bone marrow derived mesenchymal stem cells | Arm Label: Observation Group 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Observation Group 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Observation Group 3; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control Group 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Allogeneic bone marrow derived mesenchymal stem cells; Assigned to Arm(s): Active/Treatment Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I-II Randomized Autologous Bone Marrow Derived Aldehyde Dehydrogenase-Bright (ALDHbr) Cells Against Unfractionated Autologous Mononuclear Bone Marrow in Patients With Rutherford 4 or 5 Peripheral Arterial Occlusive Disease
Brief Summary: This study will treat patients with such severe lower leg ischemia or vascular compromise that they have pain at rest. The goal is to compare treatment of the patient's painful disorder by injecting cells into the calf of the leg and testing for circulatory improvement. A treatment will given at random to two groups and will be injection into the calf muscle with ALD-301 (specially processed stem and progenitor cells) from the patient's own bone marrow, or with cells processed by more routine that minimally purifies the cells. The study goal is to see if the ALD-301 cells are more effective in generating new small blood vessels to improve the circulation to the affected leg.


Options:
A: Arm Label: mesenchymal stem cells; Type: EXPERIMENTAL; Interventions: Drug: mesenchymal stem cells | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Plasmalyte A | Intervention Type: DRUG; Name: mesenchymal stem cells; Assigned to Arm(s): mesenchymal stem cells | Intervention Type: DRUG; Name: Plasmalyte A; Assigned to Arm(s): Placebo
B: Arm Label: BM-MNC; Type: EXPERIMENTAL; Interventions: Procedure: BM-MNC preparation | Arm Label: PB-MNC; Type: EXPERIMENTAL; Interventions: Procedure: PB-MNC preparation | Intervention Type: PROCEDURE; Name: BM-MNC preparation; Assigned to Arm(s): BM-MNC | Intervention Type: PROCEDURE; Name: PB-MNC preparation; Assigned to Arm(s): PB-MNC
C: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: ALDH-br bone marrow cells vs. mononuclear bone marrow cells | Intervention Type: PROCEDURE; Name: ALDH-br bone marrow cells vs. mononuclear bone marrow cells; Assigned to Arm(s): 2
D: Intervention Type: GENETIC; Name: Autologous bone marrow cells; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The BRAIN ICU Study: Bringing to Light the Risk Factors and Incidence of Neuropsychological Dysfunction in ICU Survivors
Brief Summary: The primary purpose of this proposal will be to identify potentially modifiable risk factors of long-term cognitive impairment (i.e. development of delirium and exposure to sedative and analgesic medications) in ICU patients. The investigators will quantify the independent contribution of these risk factors to the incidence of long-term cognitive impairment, controlling for other established risk factors including age, pre-existing cognitive impairment, and apolipoprotein E (apoE) genotype. Quantifying the contributions of these modifiable risk factors will pave the way for the development of preventive and/or treatment strategies to reduce the incidence, severity and/or duration of long-term cognitive impairment and improve functional recovery for patients with critical illness.


Options:
A: Arm Label: Discussion with nurse; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: ICU Diary; Type: EXPERIMENTAL; Interventions: Other: ICU Diary | Intervention Type: OTHER; Name: ICU Diary; Assigned to Arm(s): ICU Diary
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Standardized Followup program; Type: EXPERIMENTAL; Interventions: Other: Standardized Followup program | Intervention Type: OTHER; Name: Standardized Followup program; Assigned to Arm(s): Standardized Followup program
C: Arm Label: Coping skills training; Type: EXPERIMENTAL; Interventions: Behavioral: coping skills training | Arm Label: education program; Type: ACTIVE_COMPARATOR; Interventions: Other: education program | Intervention Type: BEHAVIORAL; Name: coping skills training; Assigned to Arm(s): Coping skills training | Intervention Type: OTHER; Name: education program; Assigned to Arm(s): education program
D: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The BRAIN ICU Study: Bringing to Light the Risk Factors and Incidence of Neuropsychological Dysfunction in ICU Survivors
Brief Summary: The primary purpose of this proposal will be to identify potentially modifiable risk factors of long-term cognitive impairment (i.e. development of delirium and exposure to sedative and analgesic medications) in ICU patients. The investigators will quantify the independent contribution of these risk factors to the incidence of long-term cognitive impairment, controlling for other established risk factors including age, pre-existing cognitive impairment, and apolipoprotein E (apoE) genotype. Quantifying the contributions of these modifiable risk factors will pave the way for the development of preventive and/or treatment strategies to reduce the incidence, severity and/or duration of long-term cognitive impairment and improve functional recovery for patients with critical illness.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Pulmonary Rehabilitation | Intervention Type: OTHER; Name: Pulmonary Rehabilitation; Assigned to Arm(s): Intervention
B: N/A
C: N/A
D: Arm Label: ICU Recovery Manual & placebo supplement; Type: ACTIVE_COMPARATOR; Interventions: Other: Intensive Care Unit (ICU) Recovery Manual, Dietary Supplement: Placebo nutritional supplement | Arm Label: ICU recovery manual & amino acid (AA) supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Amino acid supplement, Other: Intensive Care Unit (ICU) Recovery Manual | Arm Label: PEPSE & placebo supplement; Type: EXPERIMENTAL; Interventions: Other: PEPSE, Other: Intensive Care Unit (ICU) Recovery Manual, Dietary Supplement: Placebo nutritional supplement | Arm Label: PEPSE & AA supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Amino acid supplement, Other: PEPSE, Other: Intensive Care Unit (ICU) Recovery Manual | Intervention Type: DIETARY_SUPPLEMENT; Name: Amino acid supplement; Assigned to Arm(s): ICU recovery manual & amino acid (AA) supplement, PEPSE & AA supplement | Intervention Type: OTHER; Name: PEPSE; Assigned to Arm(s): PEPSE & AA supplement, PEPSE & placebo supplement | Intervention Type: OTHER; Name: Intensive Care Unit (ICU) Recovery Manual; Assigned to Arm(s): ICU Recovery Manual & placebo supplement, ICU recovery manual & amino acid (AA) supplement, PEPSE & AA supplement, PEPSE & placebo supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo nutritional supplement; Assigned to Arm(s): ICU Recovery Manual & placebo supplement, PEPSE & placebo supplement

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The BRAIN ICU Study: Bringing to Light the Risk Factors and Incidence of Neuropsychological Dysfunction in ICU Survivors
Brief Summary: The primary purpose of this proposal will be to identify potentially modifiable risk factors of long-term cognitive impairment (i.e. development of delirium and exposure to sedative and analgesic medications) in ICU patients. The investigators will quantify the independent contribution of these risk factors to the incidence of long-term cognitive impairment, controlling for other established risk factors including age, pre-existing cognitive impairment, and apolipoprotein E (apoE) genotype. Quantifying the contributions of these modifiable risk factors will pave the way for the development of preventive and/or treatment strategies to reduce the incidence, severity and/or duration of long-term cognitive impairment and improve functional recovery for patients with critical illness.


Options:
A: Arm Label: Rhythm control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amiodarone, Procedure: DC-cardioversion | Arm Label: Rate control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rate Control | Intervention Type: DRUG; Name: Amiodarone; Assigned to Arm(s): Rhythm control | Intervention Type: PROCEDURE; Name: DC-cardioversion; Assigned to Arm(s): Rhythm control | Intervention Type: DRUG; Name: Rate Control; Assigned to Arm(s): Rate control
B: Arm Label: Embol-X Embolic Protection Device; Type: ACTIVE_COMPARATOR; Interventions: Device: Embol-X Embolic Protection Device | Arm Label: CardioGard Cannula; Type: ACTIVE_COMPARATOR; Interventions: Device: CardioGard Cannula | Arm Label: Standard Cannula; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Embol-X Embolic Protection Device; Assigned to Arm(s): Embol-X Embolic Protection Device | Intervention Type: DEVICE; Name: CardioGard Cannula; Assigned to Arm(s): CardioGard Cannula
C: N/A
D: Arm Label: IV acetaminophen & IV propofol; Type: EXPERIMENTAL; Interventions: Drug: IV acetaminophen & IV propofol | Arm Label: IV acetaminophen & IV dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: IV acetaminophen & IV dexmedetomidine | Arm Label: IV propofol & placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV propofol & placebo | Arm Label: IV dexmedetomidine & placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV dexmedetomidine & placebo | Intervention Type: DRUG; Name: IV acetaminophen & IV propofol; Assigned to Arm(s): IV acetaminophen & IV propofol | Intervention Type: DRUG; Name: IV acetaminophen & IV dexmedetomidine; Assigned to Arm(s): IV acetaminophen & IV dexmedetomidine | Intervention Type: DRUG; Name: IV propofol & placebo; Assigned to Arm(s): IV propofol & placebo | Intervention Type: DRUG; Name: IV dexmedetomidine & placebo; Assigned to Arm(s): IV dexmedetomidine & placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The BRAIN ICU Study: Bringing to Light the Risk Factors and Incidence of Neuropsychological Dysfunction in ICU Survivors
Brief Summary: The primary purpose of this proposal will be to identify potentially modifiable risk factors of long-term cognitive impairment (i.e. development of delirium and exposure to sedative and analgesic medications) in ICU patients. The investigators will quantify the independent contribution of these risk factors to the incidence of long-term cognitive impairment, controlling for other established risk factors including age, pre-existing cognitive impairment, and apolipoprotein E (apoE) genotype. Quantifying the contributions of these modifiable risk factors will pave the way for the development of preventive and/or treatment strategies to reduce the incidence, severity and/or duration of long-term cognitive impairment and improve functional recovery for patients with critical illness.


Options:
A: Arm Label: Enteral melatonin 0.5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melatonin | Arm Label: Enteral melatonin 2 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melatonin | Arm Label: Enteral matched placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Melatonin; Assigned to Arm(s): Enteral melatonin 0.5 mg, Enteral melatonin 2 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Enteral matched placebo
B: N/A
C: Arm Label: Patients (Controls); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Behavioral: Phys & Func Rehab; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral: Physical and functional rehabilitation | Arm Label: Behavioral: Cog/Phys/Func Rehab; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral: Cognitive, physical, & functional rehabilitation | Intervention Type: BEHAVIORAL; Name: Behavioral: Physical and functional rehabilitation; Assigned to Arm(s): Behavioral: Phys & Func Rehab | Intervention Type: BEHAVIORAL; Name: Behavioral: Cognitive, physical, & functional rehabilitation; Assigned to Arm(s): Behavioral: Cog/Phys/Func Rehab
D: Arm Label: PS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Protocolized Sedation | Arm Label: PS + DI; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Protocolized sedation, with daily interruption | Intervention Type: PROCEDURE; Name: Protocolized Sedation; Assigned to Arm(s): PS | Intervention Type: PROCEDURE; Name: Protocolized sedation, with daily interruption; Assigned to Arm(s): PS + DI

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Promoting Parental Skills and Enhancing Attachment in Early Childhood
Brief Summary: Child psychological/behavioural disorders such as withdrawal may persist when the psychosocial context is unfavourable. Health promotion strategies (Olds' paradigm) have proved their efficacy in vulnerable populations. CAPEDP project sets out to evaluate a program of home visits in France


Options:
A: Arm Label: Treatment 2: Transportation, Child Screening/Referral; Type: N/A; Interventions: N/A | Arm Label: Treatment 4: Nurse Home Visiting through Age 2; Type: N/A; Interventions: Behavioral: Nurse Home Visiting | Intervention Type: BEHAVIORAL; Name: Nurse Home Visiting; Assigned to Arm(s): Treatment 4: Nurse Home Visiting through Age 2
B: Intervention Type: BEHAVIORAL; Name: Home Visiting; Assigned to Arm(s): N/A
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Promoting Parental Skills and Enhancing Attachment | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: had home visits by community workers during pregnancy | Intervention Type: BEHAVIORAL; Name: Promoting Parental Skills and Enhancing Attachment; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: had home visits by community workers during pregnancy; Assigned to Arm(s): 1
D: Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Behavioral education; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral education intervention | Intervention Type: BEHAVIORAL; Name: Behavioral education intervention; Assigned to Arm(s): Behavioral education

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Xylitol Adult Caries Trial (X-ACT)
Brief Summary: The purpose of the trial is to determine the extent to which daily use of xylitol lozenges reduces the appearance of new caries lesions in adults who tend to experience such lesions (i.e., caries-active adults).


Options:
A: Arm Label: xylitol wipe; Type: EXPERIMENTAL; Interventions: Dietary Supplement: xylitol wipe | Arm Label: placebo wipe; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo wipe | Intervention Type: DIETARY_SUPPLEMENT; Name: xylitol wipe; Assigned to Arm(s): xylitol wipe | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo wipe; Assigned to Arm(s): placebo wipe
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Sorbitol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Xylitol | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Xylitol + BB12 | Intervention Type: DIETARY_SUPPLEMENT; Name: Sorbitol; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Xylitol + BB12; Assigned to Arm(s): 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Xylitol; Assigned to Arm(s): 2
C: Arm Label: A, observation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: A, erythritol | Arm Label: B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: xylitol | Arm Label: C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: C, sorbitol | Intervention Type: DIETARY_SUPPLEMENT; Name: A, erythritol; Assigned to Arm(s): A, observation | Intervention Type: DIETARY_SUPPLEMENT; Name: xylitol; Assigned to Arm(s): B | Intervention Type: DIETARY_SUPPLEMENT; Name: C, sorbitol; Assigned to Arm(s): C
D: Arm Label: xylitol lozenge; Type: EXPERIMENTAL; Interventions: Dietary Supplement: xylitol | Arm Label: inactive lozenge; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: inactive lozenge | Intervention Type: DIETARY_SUPPLEMENT; Name: xylitol; Assigned to Arm(s): xylitol lozenge | Intervention Type: DIETARY_SUPPLEMENT; Name: inactive lozenge; Assigned to Arm(s): inactive lozenge

Answer: D